Piper Sandler lowered the firm’s price target on Cytek Biosciences (CTKB) to $8 from $8.25 following quarterly results. The firm keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTKB:
- Cytek Biosciences Reports Mixed Earnings Amid Growth and Challenges
- Strategic Resilience and Market Expansion Justify Buy Rating for Cytek Biosciences Despite Revenue Guidance Challenges
- Cytek Biosciences Reports Growth and Strategic Expansion
- Cytek Biosciences reports Q4 revenue $57.48M, consensus $59.38M
- Cytek Biosciences sees FY25 revenue $204M-$212M, consensus $216.52M